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Percutaneous Endoscopic Gastrostomy Tube Insertion in 
Neurodegenerative Disease: A Retrospective Study and Literature 
Review
Pamela Sarkar1,2, Alice Cole2, Neil J. Scolding1,2 and Claire M. Rice1,2
1Department of Neurology, Southmead Hospital, Bristol, 2Clinical Neuroscience, School of Clinical Sciences, University of Bristol, Bristol, UK
Background/Aims: With the notable exceptions of dementia, stroke, and motor neuron disease, relatively little is known about the 
safety and utility of percutaneous endoscopic gastrostomy (PEG) tube insertion in patients with neurodegenerative disease. We aimed 
to determine the safety and utility of PEG feeding in the context of neurodegenerative disease and to complete a literature review in 
order to identify whether particular factors need to be considered to improve safety and outcome.
Methods: A retrospective case note review of patients referred for PEG insertion by neurologists in a single neuroscience center 
was conducted according to a pre-determined set of standards. For the literature review, we identified references from searches of 
PubMed, mainly with the search items “percutaneous endoscopic gastrostomy” and “neurology” or “neurodegenerative disease.” 
Results: Short-term mortality and morbidity associated with PEG in patients with neurological disease were significant. Age greater 
than 75 years was associated with poor outcome, and a trend toward adverse outcome was observed in patients with low serum 
albumin. 
Conclusions: This study highlights the relatively high risk of PEG in patients with neurodegenerative disease. We present points for 
consideration to improve outcome in this particularly vulnerable group of patients. Clin Endosc  2016 Oct 13. [Epub ahead of print]
Key Words: Percutaneous endoscopic gastrostomy; Neurodegenerative diseases; Multiple sclerosis; Parkinson disease; Motor neuron 
disease
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INTRODUCTION
Percutaneous endoscopic gastrostomy (PEG) has been a 
recognized method of administration of long-term enteral 
feeding since the 1980s.1 The continuity of feeding and aspira-
tion rates of PEG compare favorably with those of nasogastric 
feeding.2 PEG feeding may be considered if nutritional intake 
is expected to be qualitatively or quantitatively inadequate for 
a period exceeding 2 to 3 weeks,3 and increases in serum albu-
min, a marker of nutritional status, have been demonstrated 
after PEG tube placement.4
The potential for PEG as a means of artificial enteral nutri-
tion in patients with neurological disease was quickly appre-
ciated.5 In these circumstances, dysphagia—with consequent 
risk of airway obstruction, dehydration, weight loss, salivary 
dribbling, and aspiration pneumonia4—is the most common 
indication for artificial enteral nutrition.6 The effort of eating 
and time taken to feed during the day may be considerable, 
with each mouthful taking 12 to 15 times longer to chew.7 
However, prior to insertion of an enteral feeding tube, the 
clinical context, diagnosis, prognosis, ethical issues, anticipat-
ed effect on quality of life, and the patient’s wishes must be 
taken into account.2
Postprocedure morbidity and mortality of PEG tube in-
sertion were reported previously, but few studies examined 
patients with neurological disease in isolation (Table 1).2,4,5,7-28 
The overall complication rate after endoscopic placement 
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Table 1. Historical Comparison with Selected Series Investigating Safety and Utility of Percutaneous Endoscopic Gastrostomy Tube Insertion 
Study Indication,% Date of series
Size of 
series, n
Mean age, 
yr
Complication 
rate, %
30-Day 
mortality, %
Löser et al. 
(1998)2
Neurological (42), ENT (28), medical (30) 1991–1995 210 61.3 24 0
Hull et al. 
(1993)5
Cerebrovascular disease (33), MND (27), MS (8), 
head and neck cancer (16), miscellaneous (16)
1988–1992 49 64 22 2
Rabeneck et al. 
(1996)21
Cerebrovascular disease (19), other organic 
neurological disease (29), head and neck cancer 
(16), miscellaneous (36)
1990–1992 7,369 68.1 4 23.5
Sanders et al. 
(2000)13
Oropharyngeal malignancy (18), stroke (33), 
dementia (29), miscellaneous (20)
1992–1997 361 66.9 29 28
Leeds et al. 
(2010)22
Cognitive impairment (2), stroke (11), oropha-
ryngeal cancer (30), neurological cancer (34), 
other (23)
2004–2007 233 61.6 NA 10.7
Tominaga et al. 
(2010)18
Malignant disease (27), cerebrovascular disease 
(32), neurodegenerative disease (23), poor 
recovery post operation (16), dementia (14)  
1998–2007 84 60.3 46 0
Arora et al. 
(2013)16
Malnutrition (18), stroke (20), other neurological 
indication (20), head and neck cancer (5), de-
mentia (5), head trauma (5), miscellaneous (27)
2006 181,196 71 NA 10.8
Burney et al. 
(2015)11
Head and neck cancer (100) 1997–2010 560 59.6 18 0
Khokhar et al. 
(2005)12
Cerebrovascular disease (96), Parkinson’s disease 
(3), malignancy (1)
1995–2004 182 NAa) 15 0
Luman et al. 
(2001)9
Cerebrovascular disease (60), Parkinson’s and 
neuromuscular disease (11), nasopharyngeal 
and gastrointestinal malignancy (25), head 
injury (4)
1995–2000 181 Median 
70.5 
56 11.5
Janes et al. 
(2005)17
Cerebrovascular disease, nasopharyngeal ma-
lignancy, MS, MND (information regarding 
proportions NA)
2001–2002 112 67.5 33 22
Nicholson et al. 
(2000)23
Cerebrovascular disease (58), other neurological 
disease (15%), oesophageal obstruction (9), 
debilitation (18)
1996–1998 168 Median 
70 
2 10
Zalar et al. 
(2004)24
Cerebrovascular disease (38), dementia (27), 
dysphagia in the elderly (10), MND & MS (10), 
neurosurgical disease (6), Parkinson’s disease 
(3), CNS neoplasia (3), encephalopathy (2)
NA 99 75 32 1
Britton et al. 
(1997)7
MND (38), MS (38), Parkinson’s disorders and 
related disorders (6), Myotonic dystrophy (6), 
Miscellaneous (12) 
1992–1995 32 49 41 0
Shimizu et al. 
(2007)25
MND (29), Parkinson’s disease (25), MSA (17), 
miscellaneous (32)
2003–2006 157 NA 9 NAb)
James et al. 
(1998)10
Stroke (100) 1991–1995 126 Median 
80
50 28
Rio et al. 
(2010)26
MND (100) 1999–2006 21 61.9 33 5
Czell et al. 
(2013)19
MND (100) NA 26 65 15 4
Spataro et al. 
(2011)8
MND (100) 2000–2007 76 59.5 0 6
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of an enteral feeding tube is variously reported to be 0% to 
57%.8,9 Local wound infection is the most common early com-
plication (15%),3 but peristomal abdominal pain, fever, and 
transient leakage of the stomach contents from the granulat-
ing puncture canal may also occur.3 Long-term complications 
may include occlusion of and leakage from the tube and site 
infections.6,10
Mortality rates (30-day postprocedure) of between 0% and 
28% have been reported.10-13 Although not all studies have 
examined PEG placement in the context of neurological dis-
ease, some neurological conditions have been associated with 
adverse outcome; patients for whom the indication for PEG 
tube insertion was dysphagia secondary to stroke and demen-
tia had 30-day mortality rates of 28%.10,13 Other predictors 
of poor outcome include a history of >10% weight loss and 
forced vital capacity (FVC) <65% of the predicted value.14 The 
UK National Confidential Enquiry into Patient Outcome and 
Death in 2004 estimated that 43% of PEG-related deaths oc-
curred in the first 7 days postprocedure, and aspiration pneu-
monia was frequently implicated as the cause of death.29 Since 
then, standards and recommendations for PEG insertion have 
been issued by the European Society of Clinical Nutrition 
and Metabolism (ESPEN, 2005)3 and the National Institute 
for Health and Clinical Excellence (NICE guideline 32, 2006) 
(Table 2).30
Neurodegenerative diseases present challenges to feeding 
and nutrition that are significantly different from those of 
trauma or stroke, but have not previously been extensively 
studied despite increasingly widespread recommendations 
for early recourse to PEG in these conditions. We therefore 
assessed PEG tube placement and outcome in patients with 
neurodegenerative disease through a retrospective case note 
review in a single neuroscience center in the UK. Our aim was 
to review clinical practice and identify potential areas for im-
provement. In the light of our results, we highlight a number 
of points that might improve patient safety when planning 
Table 2. Published Standards for PEG Insertion
Standard Guideline
FVC should be recorded for patients with MND patients ESPEN3
M easurement of renal function, glucose, liver function, bone profile, albumin, clotting, and C-reactive protein 
prior to PEG tube insertion
NICE30
Formal assessments of swallow should be undertaken prior to PEG NICE30
Daily review of stoma site following PEG tube insertion NICE30
PEG, percutaneous endoscopic gastrostomy; FVC, forced vital capacity; MND, motor neuron disease; ESPEN, European Society of Clinical 
Nutrition and Metabolism; NICE, National Institute for Health and Clinical Excellence.
Table 1. Continued
Study Indication,% Date of series
Size of 
series, n
Mean age, 
yr
Complication 
rate, %
30-Day 
mortality, %
Chiò et al. 
(1999)14 
MND (100) 1993–1998 50 61.7 2 2
Allen et al. 
(2013)20
MND (100) 2009–2012 100 61.7 16 7
Forbes et al. 
(2004)27
MND (100) 1989–1998 142 66.8 NA 25
Mazzini et al. 
(1995)4
MND (100) 1991–1993 31 60.9 NA NA
Russ et al. 
(2015)28 
MND (100) 2010–2013 21 58.9 29 5
ProGas Study 
Group (2015)15
MND (100) 2010–2014 169 64.2 24 3
Current study Parkinson’s disease and related disorders (32), 
MS (32), MND (34)
2009–2013 40 61 87.5 8
ENT, ear, nose and throat; MND, motor neuron disease; MS, multiple sclerosis; NA, not available; CNS, central nervous system; MSA, mul-
tiple system atrophy.
a)Range 55 to 86 years; b)6-month mortality 6%.
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PEG tube placement in patients with neurodegenerative dis-
ease.
MATERIALS AND METHODS
A retrospective case note review was performed. All consec-
utive cases referred for PEG tube placement by neurologists 
between 2009 and 2013 were identified from the database held 
by the Endoscopy Unit at North Bristol National Health Ser-
vice (NHS) Trust, a regional neuroscience center in the UK. 
Those patients in whom the indication for PEG was stroke 
were excluded. No patients with a diagnosis of dementia were 
referred.
Medical records were reviewed, and outcomes were mea-
sured against a pre-determined set of standards including an 
assessment of FVC, blood tests (analysis of renal function, 
glucose, liver function tests, bone profile, albumin, coagula-
tion, and C-reactive protein), formal assessment of swallow, 
and daily checks of the stoma site post-PEG tube insertion. 
Length of hospital stay, short-term complications (symptoms 
or signs within 30 days of PEG), and long-term complications 
(symptoms or signs more 30 days after PEG tube insertion) 
were recorded. Major complications were defined as per ES-
PEN guidelines and included sepsis, perforation, and hemor-
rhage,3 as well as mortality. Delay in discharge was defined as 
>3 days.
Statistics were calculated using GraphPad Prism version 6.0 
(GraphPad Software Inc., La Jolla, CA, USA). Values of p<0.05 
were considered statistically significant as determined by Kru-
skal-Wallis one-way analysis of variance with Dunn’s multiple 
comparisons test or Fisher exact test. 
RESULTS 
Patient characteristics
Forty-two patients were identified. Two (5%) were exclud-
ed because their case records were unavailable (Table 3). All 
patients had a diagnosis of motor neuron disease (MND), a 
parkinsonian syndrome (idiopathic Parkinson’s disease [PD] 
or a Parkinson’s plus syndrome [PD+]), or multiple sclerosis 
(MS). The patients were evenly distributed between each of 
these three disease groupings. The mean duration of follow 
up was 1.65 years (median, 1.4; maximum, 5). In keeping with 
the natural history, patients with MND had a shorter disease 
course from onset of disease to PEG (p<0.001). Patients with 
MS were younger at the time of PEG tube insertion (p<0.0005). 
Nineteen patients (48%) patients died within the follow-up 
period. The mean time from PEG tube insertion to death 
was 1.01 years (median, 0.83) with no significant difference 
between the disease groupings in time to death from PEG. No 
significant differences were found between the sexes in age at 
PEG tube insertion, time from disease onset to PEG, or time 
of PEG to death. 
PEG insertion
Patients fasted prior to PEG insertion which was performed 
under sedation. Esophagogastroduodenoscopy was performed 
with aspiration of stomach contents and gastric insufflation. 
The abdominal wall was transilluminated to identify the site 
for PEG insertion. Using sterile technique, local anesthesia 
was applied to the skin and the PEG tube was inserted via the 
“pull” technique. A single dose of a broad-spectrum antibiotic 
was administered if the patient was not already receiving anti-
biotics with appropriate gram-positive cover.
Table 3. Cohort Characteristics 
Disease
No. of 
patients, 
n (%)
Sex, male/
female
Age at PEG tube 
insertion, yr, 
mean (median)
Time from disease 
onset to PEG tube 
insertion, yr,  mean 
(median)
Duration of 
follow-up, yr, 
mean 
(median)
Time from PEG 
tube insertion to 
death, yr,  mean 
(median)
P arkinson’s disease and 
related disorders
13 (32) 10/3 65 (64) IPD 16.2 (18) 
MSA 6.3 (6)
PSP 6.5 (6.5)
2.25 (1.5) 1.25 (1.2)
Multiple sclerosis 13 (32) 7/6 50 (52)a) RRMS 13 (13)
PPMS 10 (10)
SPMS 20.4 (17.5)
1.68 (1.4) 1 (0.79)
Motor neuron disease 14 (34) 4/9 68 (72) 1.2 (1)a) 1.02 (1.08) 0.93 (0.83)
Total 40 (100) 21/18 61 (60) 10.2 (8) 1.65 (1.4) 1.01 (0.83)
PEG, percutaneous endoscopic gastrostomy; IPD, idiopathic Parkinson’s disease; MSA, multiple system atrophy; PSP, progressive supra-
nuclear palsy; RRMS, relapsing remitting multiple sclerosis; PPMS, primary progressive multiple sclerosis; SPMS, secondary progressive 
multiple sclerosis.
a)Statistically significant results.
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Morbidity and mortality associated with PEG  
insertion
Eighty-eight percent of patients experienced a complication 
secondary to PEG tube at some point. Multiple complications 
occurred in 12 patients (30%). Short-term complications (within 
the first 30 days) were observed in 27 patients (68%), and long-
term complications occurred in 11 patients (28%). Notably, 
some patients experienced more than one complication (Table 
4). Major short-term complications included five cases of re-
spiratory infections, one case of intra-abdominal sepsis, and 
two cases of wound infections at the stoma site that required 
antibiotic therapy. Delayed hospital discharge of greater than 
6 weeks occurred in two cases (5%). 
The 30-day mortality was 3/40 (8%) (Table 1), and the cause 
of death was aspiration pneumonia in all three cases. In one 
patient (with a parkinsonian condition), death occurred with-
in 16 hours of the procedure. Aspiration was attributed to 
disease progression in the case of one patient with MND in 
whom discharge was delayed secondary to social factors. A 
patient with secondary progressive MS died within 10 days of 
PEG. Longer term survival was determined by the underly-
ing disease process rather than by the presence or absence of 
complications secondary to PEG tube insertion; MND was as-
sociated with significantly increased risk of death (odds ratio 
[OR], 11.08; p<0.05). 
Relatively few long-term complications, which are defined 
by adverse events attributable to PEG tube insertion occurring 
after the first 30 days, were observed (Table 5). Thirty-five per-
cent of patients had major long-term complications including 
death, although death was not attributable to PEG in this time 
period. One MND patient elected not to undergo re-siting of 
PEG when the original tube was removed due to recurrent 
site infection.
Compliance with standards
Measurement of FVC
Documentary evidence for FVC measurement was avail-
able in 57% of patients with MND. Increased incidence of 
complications was not observed in patients who did not have 
monitoring. 
Availability of blood test results
All patients had blood test results available at the time of 
PEG tube insertion although four patients (10%) did not have 
a full set of blood tests.30 No difference in complication rate 
existed between those who had a full set of blood tests and 
those who did not.
Table 4. Short Term Complications (Onset within 30 Days of Percutaneous Endoscopic Gastrostomy Tube Insertion)
Complication Parkinson’s disease and related disorders Multiple sclerosis
Motor neuron
disease Total
Major
Infection at stoma site 0 1 1 2 
Aspiration pneumonia 1 3 1 5 
Abdominal sepsis 0 0 1 1 
Raised inflammatory markers 0 1 0 1 
Vomiting 0 0 1 1 
Death 1 1 1 3 
Any short term major complication 2 6 5 3 
Minor 
Dislodgement 1 0 0 1 
Pain at stoma site 3 2 4 9 
Discharge/bleeding 1 2  1 4 
Diarrhoea 0 0 2 2 
Constipation 0 0 1 1 
Any short term minor 5 4 8 17
Any short term complication 7 10 13 30 
No short term complication 6 6 2 14 
Values are presented as number.
Some patients experienced more than one complication.
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Formal swallow assessment
All patients had a formal swallow assessment by the Speech 
and Language Therapy team prior to PEG tube insertion, and 
a gastrostomy was considered appropriate in all.
Stoma site checks
Documentary evidence of daily stoma site review during 
in-patient stay was available in 21/40 (53%) patients. Of the 19 
patients who did not have a recorded daily stoma review, sev-
en patients had major complications, and three patients died. 
However, a significant relationship was not observed between 
daily stoma site check and risk of death (OR, 0.13; p=0.187), 
major complications (OR, 0.52; p=0.348), or minor complica-
tions (OR, 1.97; p=0.4601).
Patient age
Eight patients (four PD patients and four MND patients) in 
our cohort were aged >75 years of age, six of whom had major 
complications (including one death), and the OR for major 
complications with age >75 years was 10.71 (p=0.009). 
Duration of in-patient stay
Forty percent of patients (16/40) were discharged within 72 
hours of PEG placement. Delays in discharge were observed 
in all disease groups. For those patients whose hospital stay 
exceeded 3 days, discharge delays were categorized as “social,” 
“medical,” or “mixed.” Social causes were responsible for 11/24 
(46%) delays and included delays incurred setting up home-
care or training carers/patient for PEG tube use. Lack of 
dietician availability over the weekend may have contributed 
to this. Complications contributed to delays in 13/24 (54%). 
A trend toward longer in-patient stays was observed among 
those with MS; four patients (10%) remained as an in-patient 
for >1 month post-PEG tube insertion, which was pre-domi-
nantly attributable to social factors. 
Serum albumin
Not all patients had formal dietetic review prior to PEG 
tube insertion although all were observed prior to discharge. 
Albumin levels were recorded pre- (up to 10 days prior to 
procedure) and post- (up to 1 year) in 36/40 (90%) of patients. 
Twenty percent (9/36) were malnourished at the time of PEG 
tube placement as defined by serum albumin ≤30 g/L. Of the 
three patients who died within 30 days of PEG, two (67%) 
had low albumin levels (29 and 19 g/L). A strong trend to-
ward increased 30-day mortality was found if pre-procedure 
serum albumin level was ≤30 g/L (30-day mortality OR, 7.43; 
p=0.148). Statistical significance was not reached probably due 
to the low numbers of deaths. Serum albumin levels improved 
post-PEG tube placement in all patients for whom data were 
available. 
Table 5. Long Term Complications (Onset after 30 Days from Percutaneous Endoscopic Gastrostomy Tube Insertion)
Complication Parkinson’s disease and related disorders Multiple sclerosis
Motor neuron 
disease Total
Major
Aspiration pneumonia 3 3 1 7
Wound infection at PEG site 1 0 1 2
Death 0 1 6 7
Any major complication 4 4 8 16
Minor
PEG tube change 3 (infection at site, routine 
re-siting, dislodgement)
1 (dislodgement) 0 4
PEG tube removal 0 0 1 (infection at site) 1
Pain associated with PEG use 1 1 0 2
Hypergranulation 1 0 0 1
Any minor complication 5 2 1 8
Any long term complication                  9 6 9 24
No long term complications               6 8 4 18
Values are presented as number.
Some patients experienced more than one complication.
PEG, percutaneous endoscopic gastrostomy.
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DISCUSSION 
Maintaining adequate nutrition remains an important goal 
in the optimum management of many illnesses, including neu-
rodegenerative diseases. A number of studies have reviewed 
morbidity and mortality following PEG tube insertion except 
those with MND;15 the studies which have included patients 
with neurological disease have tended to include them 
among a wide range of indications for PEG (Table 1). For 
those with orofacial tumors, gastrointestinal malignancy, and 
cerebrovascular disease, a PEG tube is typically inserted to 
primarily provide temporary nutritional support and may be 
inserted prophylactically when dysphagia and weight loss are 
anticipated; circumstances are different to those encountered 
in the context of neurodegenerative disease when neuro-
logical deterioration and indefinite use of PEG tube feeding 
are expected. Outcomes are not therefore directly compa-
rable between neurodegenerative disease and other disease 
groupings; morbidity and mortality would be expected to be 
higher in the context of progressive neurological disease. Al-
though the limitations of our study include its retrospective 
nature and lack of patient and/or carer reported outcome 
measures, our study is unique in exploring in detail pre- and 
post-PEG care in a relatively large, contemporaneous cohort 
of patients with MS and parkinsonian conditions in a single 
neuroscience center in the UK. 
As expected, the 30-day mortality rate (8%) is high when 
compared with that in studies on head and neck neoplasia 
but compares favorably with those with more comparable 
patient cohorts, including those with a high proportion of 
patients in whom the indication for PEG tube insertion was 
dementia, stroke, and MND (Table 1).
Concern regarding the relatively high complication rate 
of PEG tube placement has previously been raised, and the 
National Patient Safety Agency (NPSA) published a rapid 
response report (RRR) in March 2010.31 The report included 
recommendations for good practice, such as regular observa-
tion post-PEG tube insertion, daily examination, prompt dis-
charge after the procedure, and inclusion of a “Alert Label” in 
the patient’s case record to raise awareness of the early signs 
of complications among hospital staff as well as patients, 
relatives, and carers.31 This was introduced after the onset of 
our study, and it would be of interest to know whether the 
recommendations led to a reduction in morbidity and mor-
tality associated with PEG tube insertion. 
We report a relatively high rate of complications. The high 
rate is likely to be due to multiple factors including the inher-
ent morbidity and poor conditioning associated with neuro-
degenerative disease, poor baseline nutritional status, ongoing 
risk factors for aspiration associated with neurodegenerative 
disease, and long in-patient stay with consequent increased 
susceptibility to infection but also the opportunity for im-
proved ascertainment of complications. 
Previously reported risk factors for PEG tube insertion 
include increasing age.16,17 This finding was replicated in our 
study; the OR was >10 for the risk of major complications in 
those aged >75 years. This result suggests that particular care 
should be taken when considering PEG tube feeding in the 
elderly when the indication is progressive neurological dis-
ease. 
Earlier involvement of nutritional support teams probably 
leads to earlier consideration of PEG, averting malnutrition 
and the associated increased risk of morbidity and mor-
tality. Low serum albumin was reported to be a risk factor 
for death associated with PEG tube insertion,5,17,18,32 and a 
trend toward this was replicated in our study. The low total 
number of deaths makes statistical analysis unreliable. Other 
reported prognostic factors that influence PEG outcome 
include low serum cholesterol level, low lymphocyte count, 
hyponatremia, and severe comorbidity such as cardiovas-
cular disease.17,33,34 Although one study reported that FVC 
<65% is a predictor of poor outcome in MND patients,14 no 
excess morbidity and mortality were reported in other stud-
ies in MND patients whose FVC prior to PEG tube insertion 
is <50% predicted.8,19,20,35 One group reported that periproce-
dural non-invasive ventilation (NIV) may minimize risk of 
PEG tube placement in subjects with FVC <50%,19 and the 
ESPEN guidelines recommended that PEG tube placement 
be considered prior to the FVC falling below 50% predict-
ed.3 No data are available regarding FVC measurement in 
patients with other neurological diseases in whom PEG tube 
insertion is being considered. FVC was not routinely mea-
sured in our cohort when the indication for PEG tube place-
ment was a condition other than the MND. 
Radiologically inserted gastrostomy (RIG) is an alterna-
tive to PEG tube insertion. An advantage of RIG is that the 
procedure can be undertaken while the patient receives re-
spiratory support with NIV.36,37 Allen et al.20 reported lower 
failure rates of RIG tube insertion (16% vs. 2%), but failure to 
site PEG was not a complication observed in our study. More 
significantly, however, RIG tube placement was less fre-
quently associated with aspiration (11% vs. 0%),20 although 
Shaw et al.38 reported equivalent post-procedural survival for 
patients with MND who underwent RIG or PEG tube in-
sertion. Peroral image-guided gastrostomy (PIG) is a hybrid 
technique that has been utilized with MND patients with the 
possibility of concomitant use of NIV, with rates of compli-
cations comparable to PEG (21% in PIG and 23% in PEG), 
with no reported life-threatening complications and no sig-
nificant survival differences in this study.39 In a recent large 
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prospective cohort study of amyotrophic lateral sclerosis, 
comparison of the three methods of gastrostomy insertion 
(PEG, RIG, and PIG) showed no difference in 30-day mor-
tality, survival times, or periprocedural complications, apart 
from higher perioperational distress experienced by patients 
undergoing PEG tube insertion. Mortality in this context 
was associated with increasing patient age at the onset of the 
disease and percentage of weight loss from diagnosis to the 
time point of gastrostomy.15
This study provides a snapshot of the safety and utility 
of PEG in a single neuroscience center in the UK as well as 
highlights key aspects of care that can be optimized to im-
prove morbidity and mortality, particularly for those patients 
with neurodegenerative disease. Careful patient selection, op-
timal timing of PEG tube insertion, and periprocedural care 
with comprehensive education of patients and carers as well 
as prompt, well-supported hospital discharge, would be ex-
pected to reduce morbidity, mortality, and cost-effectiveness. 
In light of this, we have outlined points of consideration for 
clinicians considering PEG tube insertion in patients with 
degenerative neurological disease (Table 6). Future prospec-
tive studies could explore a larger cohort of patients includ-
ing those who have PEG tube insertion outside a tertiary re-
ferral center, incorporate data regarding comorbidities, such 
as cardiac risk factors17 and patient and/or carer reported 
outcomes, and assess value added by input from a dedicated 
nutrition team and radiological guidance of gastrostomy 
tube insertion. 
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